Zomedica Pharma

78 articles with Zomedica Pharma

• Zomedica Enters Into Strategic Investment and Potential Collaboration for VetGuardian Monitoring Product Line

  5/19/2022

  Zomedica Corp. announced that it has purchased a $1.0 million convertible note from Structured Monitoring Products, Inc., makers of the VetGuardianTM wireless remote pet monitoring platform, and in connection therewith has acquired the option to act as a sales agent for SMP's platform.

• Zomedica Announces First Quarter 2022 Revenues of $3.8 Million; 74% Gross Margin & $192.3 Million in Cash; Revenue up 38% from 2021 Combined Revenues

  5/10/2022

  Zomedica Corp., a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, reported consolidated financial results for the three months ended March 31, 2022.

• Zomedica to Present at H.C. Wainwright Global Investment Conference

  4/27/2022

  Zomedica Corp. announced that Larry Heaton, Chief Executive Officer, will provide a strategic update and discuss first quarter 2022 earnings at the upcoming H.C. Wainwright Global Investment Conference, scheduled for 11:30 am ET on May 24, 2022.

• Zomedica's Announces Designation of Pulsevet System as the Official Shock Wave Therapy of the American Quarter Horse Association

  4/13/2022

  Zomedica Corp. is pleased to announce that the PulseVet system has been named the Official Shock Wave Therapy of the American Quarter Horse Association.

• Zomedica Corporation Reports 2021 Fourth Quarter & Full Year Results

  3/1/2022

  Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, reported consolidated financial results for the year ended December 31, 2021.

• Zomedica Announces Fourth Quarter and 2021 Revenues of $4.1 Million; 73.9% Gross Margin

  2/25/2022

  Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, announced revenues and gross margin for the Fourth Quarter and Full Year 2021.

• Zomedica Appoints Adrian Lock to Lead Sales Organization

  2/15/2022

  Zomedica Corp. announced that Adrian Lock, Vice President and General Manager, will lead the Company's sales organization, including Zomedica field sales personnel, sales management and professional service veterinarians, as well as existing PulseVet sales personnel.

• Zomedica Provides Updates on PulseVet Sales & Marketing Integration and Marketing Activities for the First Quarter of 2022

  1/27/2022

  Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, provided an update on its marketing activities during the first quarter of 2022.

• Zomedica CEO Provides Update to Shareholders

  1/10/2022

  Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, issued the following letter from Larry Heaton, Chief Executive Officer, updating Zomedica's shareholders regarding several key activities and events:

• Zomedica Appoints Larry Heaton as President and Announces CEO Succession Plan

  10/4/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostic and therapeutic products for companion animals, announced that Larry Heaton has been appointed President effective October 1, 2021.

• Zomedica Provides Corporate Update - July 06, 2021

  7/6/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, provided the following corporate update:

• Zomedica Hires Vice President Business Development to Lead Acquisition and Licensing Efforts

  5/17/2021

  Former Elanco Animal Health, Johnson & Johnson, Intuitive Surgical, and Enteromedics Business Development Executive Joins Team to Support Growth Opportunities

• Zomedica Announces First Quarter 2021 Financial Results

  5/12/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, reported consolidated financial results for the three months ended March 31, 2021.

• Zomedica Announces First Commercial Sale of Its Truforma® Platform

  3/16/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization.

• Zomedica Retires Preferred Shares TRUFORMA® Progressing Toward Commercialization

  3/8/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that it has effected the exchange of all of its outstanding Series 1 Preferred Shares for its common shares and that it continues to progress with its planned commercialization of its TRUFORMA® platform.

• Zomedica Corp. Announces Year End 2020 Financial Results

  2/26/2021

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, reported consolidated financial results for the year ended December 31, 2020.

• Zomedica Corp. Announces Closing of $173.5 Million Bought Deal

  2/11/2021

  Zomedica Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that the closing of its previously announced public offering of 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions.

• Zomedica Corp. Increases Previously Announced Bought Deal Offering of Common Shares to $173.5 Million

  2/9/2021

  Zomedica Corp. announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 91,315,790 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions.

• Zomedica Corp. Announces $25.0 Million Bought Deal Offering of Common Shares

  2/8/2021

  Zomedica Corp. announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 13,157,895 common shares of Zomedica, at a price to the public of $1.90 per share, less underwriting discounts and commissions.

• Zomedica Completes Internal “Launch Team” for Upcoming TRUFORMA™ Commercialization

  12/7/2020

  Zomedica Corp., a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that, with the hiring of Debra Rock to lead the Company’s Marketing Department, its internal commercial leadership team is complete.